Pay in 4 interest-free payments of $6.23 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Among 169,649 patients with MASLD, GLP-1 receptor agonist initiation was linked to significantly lower probability of incident cirrhosis [adjusted hazard ratio (aHR): 0.86, 95%CI: 0.80-0.93], hepatic decompensation (aHR: 0.77, 95%CI: 0.65-0.90), and hepatocellular carcinoma (HCC) (aHR: 0.79, 95%CI: 0.68-0.92) over a median follow-up of 3.5 years compared to non-users
Monthly office visits to track progress and titrate dosing of the medication
The reduction in CV death with empagliflozin in patients with T2D and PAD translates to a number needed to treat of 29 patients over 3.1 years to prevent one event
The weekly monitoring can catch problems early before they become reasons to discontinue treatment
But there IS a lot of hype floating around this stack, and most of it comes from people who dont understand the underlying pharmacology or how to properly dose and cycle either compound
US$ 21.92
US$ 20.32
US$ 27.63
US$ 28.27
US$ 24.98
US$ 29.94
